CureVac NV (CureVac NV) Pretax Margin % : -383.24% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CureVac NV's Pre-Tax Income for the three months ended in Dec. 2023 was $-94.32 Mil. CureVac NV's Revenue for the three months ended in Dec. 2023 was $24.61 Mil. Therefore, CureVac NV's pretax margin for the quarter that ended in Dec. 2023 was -383.24%.

The historical rank and industry rank for CureVac NV's Pretax Margin % or its related term are showing as below:

CVAC' s Pretax Margin % Range Over the Past 10 Years
Min: -574.91 Med: -442.06 Max: -265.69
Current: -483.67

CVAC's Pretax Margin % is ranked worse than
64.72% of 1029 companies
in the Biotechnology industry
Industry Median: -172.84 vs CVAC: -483.67

CureVac NV Pretax Margin % Historical Data

The historical data trend for CureVac NV's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Pretax Margin % Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pretax Margin %

Get a 7-Day Free Trial

-574.91

-265.69

-400.52

-369.56

-483.59

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pretax Margin %	Get a 7-Day Free Trial															-1,101.50	-805.38	-889.16	-295.31	-383.24

Competitive Comparison of CureVac NV's Pretax Margin %

For the Biotechnology subindustry, CureVac NV's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where CureVac NV's Pretax Margin % falls into.

CureVac NV Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

CureVac NV's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-283.499	/	58.624
	=	-483.59 %

CureVac NV's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-94.316	/	24.61
	=	-383.24 %

CureVac NV (NAS:CVAC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

CureVac NV Pretax Margin % Related Terms

Thank you for viewing the detailed overview of CureVac NV's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.